Form 4: Clarivate PLC Director Andrew Snyder Reports Acquisition of Shares

Director Andrew Snyder reports the acquisition of Clarivate PLC shares through a transaction on March 14, 2025, and discloses beneficial ownership.

Summary

• On March 14, 2025, Andrew Miles Snyder, a director of Clarivate PLC, reported acquiring 237,176 ordinary shares at a weighted average price of $4.17.
• The prices actually paid ranged from $4.04 to $4.20, inclusive.
• Following the transaction, Snyder's direct holdings include 103,157 ordinary shares.
• Snyder also has indirect beneficial ownership through various entities including Cambridge Information Group I LLC (787,510 shares), Cambridge Information Group Inc. (8,821,984 shares), Cambridge Information Group II LLC (10,489,466 shares), Cambridge Information Group III LLC (4,033,271 shares), CSA GP Corporation (3,417 shares), and Snyder 2011 Family Trust (238,500 shares).

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing indicating a director's share purchase, which can be interpreted as a positive signal but doesn't inherently convey strong positive or negative sentiment.

Positives

• A director purchasing shares can be seen as a positive signal, indicating confidence in the company's future prospects.

Management Comments

• Andrew M. Snyder disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to the market.

Comparison to Industry Standards

• Form 4 filings are a standard regulatory requirement for corporate insiders in publicly traded companies, ensuring transparency and compliance with securities laws.
• Similar filings are made by insiders at companies like RELX Group and Thomson Reuters, which are Clarivate's main competitors in the information and analytics industry.

Stakeholder Impact

• The share acquisition by a director could positively influence shareholder confidence.

Key Dates